Replies to post #296080 on Amarin Corp Plc (AMRN)

[Will Lar]

Think one can sell the same product with different brands for different prices? How about insurances? Are they stupid enough not to notice this? They have to be entirely generic in the US. If they do that, it's harder for them to sell the same product elsewhere as a branded product.

Selling the company is the only way that they can deliver any shareholder value now. Of course, that is if they actually care about shareholders.

[MontanaState83]

ILT - I see two major problems; 1) there would be no market for branded V as generic will be used always, 2) AMRN can’t compete with generics. Not talking price here, rather stocking shelves in pharmacies. AMRN is a pretty small fish (no pun intended)

[sts66]

AMRN can't make their own GV - it's still called Vascepa, GV will be called icosapent ethyl - all AMRN can do is cut prices to match generics, but even that doesn't help in the states where generics are mandated. There was a bill passed by Congress in 2018 that forced pharmas to increase discounts for drugs sold while the patient is in the Medicare donut hole from 50% to 70%, but in states where generics must be given those Medicare patients actually pay more for the generic than the name brand - the law didn't force generics to reduce prices when patients hit the donut hole.